Actively Recruiting
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Led by Peking University People's Hospital · Updated on 2024-10-01
142
Participants Needed
14
Research Sites
76 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
X
Xiangya Hospital of Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
CONDITIONS
Official Title
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, aged between 18-65 years
- Platelet count less than 20×10^9/L or transfusion dependent on day 7 after haplo-HSCT
- Agree to receive avatrombopag treatment after haplo-HSCT and sign informed consent form
You will not qualify if you...
- Active infection
- ALT or AST higher than 3 times the upper limit of normal or total bilirubin higher than 2 times the upper limit of normal
- Creatinine clearance less than 50 mL/min
- History of arteriovenous thrombosis
- History of cardiovascular disease such as severe congestive heart failure, arrhythmia increasing thromboembolism risk, angina, or prior coronary interventions
- Treatment with platelet-promoting drugs within two weeks before enrollment
- Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody
- Known allergy to avatrombopag or its ingredients
- Secondary or multiple hematopoietic stem cell transplantations
- Pregnant, breastfeeding, or fertile females refusing contraception during and one month after trial
- Participation in other investigational clinical trials within 30 days prior to baseline visit, except observational studies
- Deemed unsuitable for enrollment by investigator due to medical history or conditions
- Use of certain medications during trial including rhIL-11, rhTPO, TPO receptor agonists, or desitabine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
2
Guangzhou First People's Hospital, School of Medicine, South China University of Technology
Guangzhou, Guangdong, China
Not Yet Recruiting
3
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Actively Recruiting
4
The First Affiliated Hospital, Harbin Medical University
Harbin, Heilongjiang, China
Not Yet Recruiting
5
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Not Yet Recruiting
6
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Not Yet Recruiting
7
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Not Yet Recruiting
8
Xiangya Hospital, Central South University
Changsha, Hunan, China, 410008
Not Yet Recruiting
9
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Not Yet Recruiting
10
Shanxi Tumor Hospital Affiliated to Shanxi Medical University
Taiyuan, Shanxi, China
Not Yet Recruiting
11
Tangdu Hospital, PLA Air Force Military Medical University
Xi’an, Shanxi, China
Not Yet Recruiting
12
Xinqiao Hospital, Army Military Medical University
Chongqing, Sichuan, China
Not Yet Recruiting
13
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, China, 650100
Not Yet Recruiting
14
Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China
Not Yet Recruiting
Research Team
H
Haixia Fu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here